Ischemix Initiates Phase 2a Trial of CMX-2043 for the Prevention of Ischemia-Reperfusion Injury

ClinicaSpace Login

Enter your ClinicaSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Clinical Research
News & Careers

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
FREE Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Date
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Today's Hot Jobs
Most Recent Jobs
Search Jobs
Post Resume
Career Resources
For Employers

COMMUNITY
Login
Become a Member
FAQ

PROFILES
Company Profiles

INDUSTRY EVENTS
Clinical

RESOURCES
Real Estate
New Business Opportunities

News | News By Subject | News By Date | Search News

Email

Ischemix Initiates Phase 2a Trial of CMX-2043 for the Prevention of Ischemia-Reperfusion Injury
3/9/2010

MAYNARD, Mass.--(BUSINESS WIRE)--Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Ischemix

• Clinical - Phase II